Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase II trial is studying how well MRI and MRSI evaluate patients who are undergoing treatment for gliomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed supratentorial glioma

• Grade II-IV disease

• Previously untreated disease

• Eligible for surgical resection and/or chemotherapy with or without radiotherapy

• Tumor accessible by magnetic resonance spectroscopic imaging

PATIENT CHARACTERISTICS:

• Karnofsky performance status 60-100%

• Life expectancy ≥ 8 weeks

• Not pregnant

• No contraindication for magnetic resonance examinations, including any of the following:

• Cardiac pacemaker or fibrillator

• Aneurysm clip

• Insulin or infusion pump

• Any implant held in place by a magnet

• Metal contamination anywhere in the body

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy

• No prior radiotherapy

• No prior treatment for the malignancy